Nile tilapia piscidin 5, TP5

General Information


DRACP ID  DRACP02335

Peptide Name   Nile tilapia piscidin 5, TP5

Sequence  QLQGKQVSGEVVQKVLQELIQSVAKP

Sequence Length  26

UniProt ID  L0CM08 

PubChem CID  Not available

Origin  Oreochromis niloticus

Type  Native peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma Low active up to 100 µg/ml MTS assay 24 h 1
RAW 264.7 Mouse leukemia Leukemia Low active up to 100 µg/ml MTS assay 24 h 1

Hemolytic Activity  Human erythrocytes: Not active up to 100 µg/ml; Tilapia erythrocytes: Not active up to 100 µg/ml

Normal (non-cancerous) Cytotoxicity  TO2: ~10% Killing=80 µg/ml; MRC-5: Low active up to 100 µg/ml

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02335

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C125H217N35O39

Absent amino acids  CDFHMNRTWY

Common amino acids  Q

Mass  328043

Pl  9.44

Basic residues  3

Acidic residues  2

Hydrophobic residues  10

Net charge  1

Boman Index  -2674

Hydrophobicity  -19.23

Aliphatic Index  119.62

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  4

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 23226256

Title  Five different piscidins from Nile tilapia, Oreochromis niloticus: analysis of their expressions and biological functions

Doi 10.1371/journal.pone.0050263

Year  2012

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPR_4200

DRACP is developed by Dr.Zheng's team.